

Proficiency Testing Program Executive Meeting Agenda

Date: 092524

Time: 11:00-12:30 Eastern

Invitation: Microsoft Teams – Invite sent through email meeting announcement

- **Welcome and Roll Call (see att. A)** **Stacie**
 - 6 Voting members present representing a quorum
 - 4 Associate members present
 - Meeting called to order at 11:03 AM and agenda approved with no additions,

- **Review Meeting Minutes** **Susan**
 - July- Approved (with minor editorial changes)
 - Motion: Amy Demarco
 - Second: Tim Miller
 - Unanimous vote to approve
 - EMS Meeting Summary (August meeting)- Approved (with minor editorial changes)
 - Motion: Tim Miller
 - Second: Patrick Selig
 - Unanimous vote to approve
 - Stacie will work with Ilona to obtain the PTPEC Action item list to include with future minutes
 - July and August minutes submitted to William for website posting.

- **PT Position Paper Status** **Susan**
 - Policy reviewed and made changes to be more specific about who does the PTPA evaluations and who assesses PT Providers
 - Ilona, Susan and Stacie provided response to suggested edits and returned to the Policy Committee.
 - Policy Committee approved the latest version and sent to the Board of Directors or final approval in October meeting.

- **Volume 3 and 4 Draft Language** **Stacie (review onscreen)**
 - Small workgroup developed draft language to include to ensure PTPAs had a role in ensuring PT Providers meet requirements to respond to PTPEC Data requests for FoPT evaluation.
 - Committee reviewed and made minor changes to changes made to ELV3 5.10.4.2 to add language specifying data submissions must be completed by a specific deadline. ELV4 5.6.2 was updated to include language requiring that the PTPA must ensure the PT Provider completed submission of data requests within the requested timeframe.
 - Committee discussed if one month was sufficient time for PT Providers to complete data submissions. It was agreed that this was an appropriate window of time. PTPEC can extend timeframe if PT Providers or PTPAs request additional time for unforeseen problems.

- Stacie will send to PT Expert Committee Chair to be reviewed and incorporated into the latest standard update.
 - Additional action will be needed to update PTPEC SOPs to include procedure for including PTPAs in all communication regarding PTPEC data requests.
- **Chlordane Nomenclature and CAS#** **Susan and Tim (see att. C)**
 - There is confusion with nomenclature and CAS# between FoPT Tables and Non-Potable Water and Solid and Chemical Materials FoPT Tables and EPA analytical methods.
 - TNI FoPT Tables have a CAS # listed for Gamma Chlordane that does not match what is used in EPA methods, which is the CAS # for trans- Chlordane. The most commonly used CAS # whether for Gamma or trans-Chlordane is 5103-74-2.
 - After extensive discussion during the meeting, it was determined additional information is needed before moving ahead with recommending any changes to FoPT Tables and LAMS.
 - Michella Karapondo will look at EPA methods and document what compound and CAS # are included.
 - Committee will check with Craig Huff for additional background based on his work with the group that added CAS#s to FoPT Tables.
 - The goal will be to ensure the FoPT Tables, LAMS and analytical methods match as much as possible.
- **Mercury NPW FoPT Concerns** **Susan and Tim**
 - There was a question concerning the correctness of the PTRL for Mercury currently listed as 0.9 ug/L on the Non-Potable Water FoPT Table. Should this be 2.1 ug/L?
 - The Chemistry FoPT Subcommittee will investigate this in their October meeting
 - If the PTRL needs to be changes, Stacie will determine if the change requires a full update of the FoPT Table, and what next steps will be.
- **Subcommittee Updates**
 - **Chemistry FoPT Subcommittee** **Amy DeMarco**
 - The last PT Provider uploaded data for the Drinking Water FoPT Review at the beginning of August for FoPT review. The subcommittee has started the review process.
 - **WET FoPT Subcommittee** **Craig Huff (absent)**
 - No update- still reviewing PT data for future PTPEC recommendation.
 - **PTPEC SOP Subcommittee** **Amanda Fehr (absent)**
 - SOP 4-101 will need to be updated.
 - Susan will work with Amanda Fehr on process for SOP Updates since this will be the first one completed under her leadership.
- **Other Business**
 - Stacie will begin managing meeting invitation as part of Program Administrator role. New recurring TEAMS meeting invite will be sent for the October meeting and all moving forward.

- **Voting Members Only: Vote in Vice-Chair Susan (Stacie conducted email vote)**
 - Amy DeMarco was nominated as Vice-Chair, and a partial committee vote was obtained from voting members present. There was no longer a quorum when this vote was conducted.
 - Motion: Tim Miller
 - Second: Marina Aziz
 - Roll Call vote all for: Amy DeMarco, Susan Jackson, Tim Miller, Jack Denby, Marina Azia
 - Email votes for: Rachel Ellis, Craig Huff, Patrick Selig, Jennifer Best, Prasanth Ramakrishnan, Amanda Fehr
 - Motion Passes unanimously
 - No abstentions or negative votes

Attachment A
Participants
TNI
Proficiency Testing Program Executive Committee

Members	Rep	Affiliation	Contact Information
Stacie Crandall Program Administrator Present		TNI	stacie.crandall@nelac-institute.org
Susan Jackson (2025*) (Chair) Present	Lab	South Carolina DES	susan.jackson@des.sc.gov
Amy DeMarco (2027*) Present	Other	NY	amy.demarco@health.ny.gov
Craig Huff (2027*) Absent	Other	Waters	craig_huff@waters.com
Tim Miller (2024*) Present	Other	Phenova	timm@phenova.com
Jennifer Best (2025*) Absent	Other	USEPA	jennifer.best@epa.gov
Jack Denby (2025*) Present	Lab/FSMO	HRSD	jdenby@hrsd.com
Rachel Ellis (2025) Absent	AB	New Jersey DEP	Rachel.ellis@dep.nj.gov
Patrick Selig (2024*) Present (left at 12:00)	AB	ANAB	pselig@anab.org
Prasanth Ramakrishnan (2024*) Absent	AB	ISA	pramakrishnan@iasonline.org
Amanda Fehr (2027*) Absent	Lab	GEL	amanda.fehr@gel.com
Marina Aziz (2027*) Present	AB	NY	marina.aziz@health.ny.gov

Associate Members Present: Charles Faulk, Michella Karapondo, Carl Kirscher, Windsor Molnar

Attachment B

Backburner / Reminders – TNI PT Executive Committee

	Item	Meeting Reference	Comments
7	Add the Field PT Subcommittee to the limit update SOP during its next update.	3/4/10	In Progress
11	Evaluate how labs are accredited for analytes that co-elute.	5-19-11	See meeting reference for details.
13	Charter needs to be reviewed/updated in November.	Ongoing	
18	Shawn noted that PTPEC should have some specific measurements. This should be passed along to the PTP SOP Subcommittee. Nicole noted that we need to determine which items to measure.	6-29-17	To be added to 2021 goals.
19	Review possible issues surrounding one vendor for Radiochemistry PTs.	3/24/23	

Attachment C (Chlordane)

NIST Chemistry WebBook				The requested CAS registry number (5566-34-7) was not found in the da		
LAMS	gamma-Chlordane	5566-34-7	7245			
LAMS	trans-Chlordane	5103-74-2	7972			
NIH PubChem	gamma-Chlordane	5566-34-7				
Chemical Book	gamma-Chlordane	5566-34-7		One Chinese source		
https://www.atsdr.cdc.gov/ToxProfiles/tp31-c4.pdf	(trans-chlordane or γ-chlordane)	5103-74-2				
40 CFR 141	Chlordane	57-74-9	LAMS:	Chlordane (NOS)	57-74-9	Chlordane (tech.)
525.3	trans-chlordane	5103-74-2				
525.2	gamma-Chlordane	5103-74-2				
525.1	γ-Chlordane	5103-74-2				
8081B 11.6.2						
<p>The nomenclature of the various forms of chlordane has been the subject of some confusion in both Agency methods and the open literature for some time. The CAS number for technical chlordane is properly given as 12789-03-6. The two most prevalent major components of technical chlordane are cis-chlordane, CAS number 5103- 71-9 and trans-chlordane, CAS number 5103-74-2. The structure represented by trans-chlordane has on occasion been mistakenly referred to by the name gamma-chlordane, and a separate CAS number of 5566-34-7 has been assigned by CAS to that designation</p>						
CDC						
<p>Sixty to 85% of technical chlordane consists of the stereoisomers cis- and trans-chlordane (Buchert et al. 1989; Worthing and Walker 1987). The ratio of the cis and trans isomers depends on the manufacturing process (Buchert et al. 1989). cis-Chlordane (1α,2α,3αα,4β,7β,7αα) is also known as α-chlordane. trans-Chlordane (1α,2 β,3αα,4β,7β,7αα) is commonly known as γ-chlordane, although it is occasionally referred to as β-chlordane (CAS 1992; EPA 1984; Worthing and Walker 1987). This is particularly confusing because γ-chlordane is also the common name of the 2,2,4,5,6,7,8,8-octachloro isomer. This toxicological profile for chlordane uses the names cis- and trans-chlordane to avoid confusion.</p>						
NIST Chemistry WebBook	cis-Chlordane	5103-71-9		Other names	α-Chlordane	
TNI NPW FoPT/LAMS	cis-Chlordane (alpha-Chlordane)	5103-71-9				
TNI SCM FoPT/LAMS	cis-Chlordane (alpha-Chlordane)	5103-71-9				
EPA 8081B (2007)	cis-Chlordane	5103-71-9				
EPA 608.3 (2016)	alpha-Chlordane	5103-71-9				
EPA 508.1 (1995)	Chlordane - alpha	5103-71-9				
525.3	cis-chlordane	5103-71-9				
525.2	alpha-Chlordane	5103-71-9				
525.1	α-Chlordane	5103-71-9				
https://www.atsdr.cdc.gov/ToxProfiles/tp31-c4.pdf	(cis-chlordane or α-chlordane)	5103-71-9				